[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-familial-intrahepatic-cholestasis-pfic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-familial-intrahepatic-cholestasis-pfic":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100615537","a-database-study-of-maralixibat-tak-625-in-participants-with-alagille-syndrome-algs-and-progressive-familial-intrahepatic-cholestasis-pfic-100615537",false,"NCT07293897","A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)","A Cohort Study to Investigate the Risk of Liver Disorder of Livmarli Oral Solution in Patients With Japan Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Registered in the Comprehensive and Informative Registry System for Childhood Liver Disease (CIRCLe)","Inclusion Criteria:\n\n* Has a diagnosis of ALGS or PFIC within the enrollment period.\n* There is a prescription for Livmarli during the enrollment period (Index date: the date of the first prescription within the enrollment period).\n\nExclusion Criteria:\n\n\\- None","ALL",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","This study is a database study in Japan for maralixibat (TAK-625) used to treat participants with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).\n\nThe main aim of the study is to evaluate the risk of liver disorder during the use of maralixibat in Japanese patients with ALGS or PFIC.\n\nThis database study will conduct in use of medical database called Comprehensive and Informative Registry system for Childhood Liver Disease (CIRCLe).",[23,24],"Alagille Syndrome (ALGS)","Progressive Familial Intrahepatic Cholestasis (PFIC)",[23,24],"RECRUITING","2026-02-18",{"date":29,"type":30},"2026-02-20","ACTUAL",{"date":32,"type":30},"2026-01-13",{"date":34,"type":19},"2031-06-30",{"name":36,"class":37},"Takeda","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100575871","familial-intrahepatic-cholestasis-related-genes-associated-with-disease-susceptibility-in-hepato-biliary-cancers-100575871","NCT06777914","Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers","Inclusion Criteria:\n\n* Instrumental or histological diagnosis of HBCs, defined as primary liver and\u002For biliary tumors (hepatocellular carcinoma, cholangiocarcinoma, hepatocholangiocarcinoma) occurring in patients without apparent underlying chronic liver disease or in the context of cryptogenic chronic liver disease;\n* Curative treatment through surgical resection of the neoplasm or liver transplantation\n* Diagnosis of CCLDs defined as:\n\n  1. GGT and\u002For alkaline phosphatase \\>1.5 times the normal values in two or more measurements taken at least 6 months apart,\n  2. A history of pruritus combined with \\[BA\\] \\>10 mmol\u002Fl for a period of ≥6 months.\n* Obtaining written informed consent\n\nExclusion Criteria:\n\n* Other documented causes of chronic liver disease that can justify the clinical phenotype include:\n\nPrimary biliary cholangitis Primary sclerosing cholangitis IgG4-related cholangiopathy Obstructive jaundice excluded by the demonstration of normal bile duct anatomy Negative virological tests for HBV, HCV, HEV Alcohol abuse Hemochromatosis Wilson's disease Alpha-1 antitrypsin deficiency","12 Months",{"count":47,"type":19},600,"This is a cross-sectional, multicenter tissue study with an exploratory aim to estimate the prevalence of genetic mutations that predispose individuals to diseases in the context of cholestatic disorders and hepatobiliary neoplasms. It is intended as a hypothesis-generating study for future empirical investigations.",[50,24,51],"Hepatobiliary Cancers","Cholestatic Liver Disease","2025-01-10",{"date":54,"type":30},"2025-01-16",{"date":56,"type":30},"2024-10-22",{"date":58,"type":19},"2027-10",{"name":60,"class":61},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",5]